Censoring (clinical trials)
From Wikipedia, the free encyclopedia
This article or section needs to be wikified to meet Wikipedia's quality standards. Please help improve this article with relevant internal links. (May 2008) |
The introduction to this article provides insufficient context for those unfamiliar with the subject. Please help improve the article with a good introductory style. |
All or part of this article may be confusing or unclear. Please help clarify the article. Suggestions may be on the talk page. (May 2008) |
This article is orphaned as few or no other articles link to it. Please help introduce links in articles on related topics. (May 2008) |
This page has few or no links to other articles. (Tagged since May 2008). You can improve this article by adding links to related material, within the existing text. For some link suggestions, you can try Can We Link It tool. (You can help!) |
Mathematically removing a patient from the survival curve at the end of their follow-up time is called censoring the patient. Censoring a patient will reduce the sample size for ananlyzing after the time of the censorship. Reducing the sample size always reduces reliability, so the more patients are censored and the earlier they are censored the more unreliable the results are.
Many clinical trials are designed with a minimum follow-up time. This means that the results aren't reported until that amount of the time after the last patient signed up for the trial. Often reports of the preliminary results don't include any minimum follow-up time and include the patients with very short follow-up time which definitely affects the reliability of the result.
[edit] References
AR Waladkhani. (2008). Conducting clinical trials. A theoretical and practical guide. ISBN 9783940934000